Arrowhead Pharmaceuticals (ARWR) Non-Current Debt (2011 - 2026)
Arrowhead Pharmaceuticals' (ARWR) quarterly Non-Current Debt came in at $159.6 million in Q1 2026, down 23.59% YoY from $208.9 million in Q1 2025, and down 2.13% on a QoQ basis from $163.1 million in Q4 2025.
Arrowhead Pharmaceuticals (ARWR) Non-Current Debt (2011 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 10 years of Non-Current Debt data on file, last reported at $159.6 million in Q1 2026.
- Quarterly Non-Current Debt fell 23.59% year-over-year to $159.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $159.6 million (down 23.59% YoY) and the FY2025 annual result came in at $214.9 million, down 45.35% from the prior year.
- Non-Current Debt fell to $159.6 million in Q1 2026, from $163.1 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $407.8 million in Q4 2024 to a low of $159.6 million in Q1 2026.
- A 3-year average of $249.7 million and a median of $208.9 million in 2025 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2025 — Non-Current Debt sank 60.0% — and 2026, when it fell 23.59%.
- Tracing ARWR's Non-Current Debt over 3 years: stood at $407.8 million in 2024, then slumped by 60.0% to $163.1 million in 2025, then dropped by 2.13% to $159.6 million in 2026.
- The last three Non-Current Debt figures came in at $159.6 million (Q1 2026), $163.1 million (Q4 2025), and $214.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Arrowhead Pharmaceuticals | 12.23 Bn | 10.63 Bn | - | 181.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 181.40 Mn |
| Mar 31, 2026 | 159.64 Mn |
| Dec 31, 2025 | 163.11 Mn |
| Sep 30, 2025 | 214.88 Mn |
| Jun 30, 2025 | 200.33 Mn |
| Mar 31, 2025 | 208.93 Mn |
| Dec 31, 2024 | 407.79 Mn |
| Sep 30, 2024 | 393.18 Mn |
| Sep 30, 2019 | 2.70 Mn |
| Jun 30, 2019 | 2.70 Mn |
| Mar 31, 2019 | 2.70 Mn |
| Dec 31, 2018 | 2.30 Mn |
| Sep 30, 2018 | 2.10 Mn |
| Jun 30, 2018 | 2.16 Mn |
| Mar 31, 2018 | 2.22 Mn |
| Dec 31, 2017 | 2.27 Mn |
| Sep 30, 2017 | 2.33 Mn |
| Jun 30, 2017 | 2.38 Mn |
| Mar 31, 2017 | 2.43 Mn |
| Dec 31, 2016 | 2.48 Mn |